Chinese Journal of Clinical Oncology
|
2025, 52(14): 727-742
Expert consensus on liquid biopsy-based multi-cancer early detection (2025 edition)
Full
Wanqing Chen
1, Kexin Chen
2, Yutong He
3, Weihua Jia
4, Zhihua Liu
1, Hongxia Ma
5, Xiaoping Miao
6, Kaifeng Pan
7, Chen Wu
1, Changfa Xia
1, Jinliang Xing
8, Yongjie Xu
1, Working Group for the Development of Expert Consensus on Liquid Biopsy-based Multi-Cancer Early Detection
- 1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021,China
- 2Department of Epidemiology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China
- 3Office of Cancer Prevention, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
- 4State Key Laboratory of Oncology in South China, Guangdong Provincial Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510050, China
- 5Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, China
- 6Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan 430071, China
- 7Department of Epidemiology, Peking University Cancer Hospital & Beijing Institute for Cancer Prevention and Research, State Key Laboratory of Gastrointestinal Cancer Precision Prevention and Integration Therapy, Beijing Key Laboratory of Carcinogenesis and Translational Research, Beijing 100142, China
- 8Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Air Force Medical University, Xi'an 710032, China
Cancer stands as a significant global public health challenge, and cancer screening serves as a pivotal strategy for reducing its mortality. Presently, only a limited number of cancer types have appropriate screening methods available. Traditional single-cancer screening approaches are fraught with limitations, including invasiveness, low accuracy, and poor patient compliance. Multi-cancer early detection (MCED) leveraging liquid biopsy technology enables non-invasive and efficient early detection of multiple cancers by analyzing biomarkers such as cell-free DNA, cell-free RNA, proteins, and metabolites in blood and other bodily fluids. This innovative approach substantially broadens the spectrum of detectable cancers and enhances population coverage, showcasing immense potential for improving existing cancer screening strategies. This expert consensus comprehensively reviews the progress of liquid biopsy-based MCED, biomarker selection and detection technologies, the criteria for cancer type selection,research design and clinical utility evaluation, as well as implementation pathways. The overarching goal of this consensus is to offer scientific guidance for further research and the widespread adoption of MCED, thereby facilitating the continuous optimization of cancer screening strategies.
Wanqing Chen, Kexin Chen, Yutong He, Weihua Jia, Zhihua Liu, Hongxia Ma, Xiaoping Miao, Kaifeng Pan, Chen Wu, Changfa Xia, Jinliang Xing, Yongjie Xu, Working Group for the Development of Expert Consensus on Liquid Biopsy-based Multi-Cancer Early Detection.
Expert consensus on liquid biopsy-based multi-cancer early detection (2025 edition)[J].
Chinese Journal of Clinical Oncology,
2025
, 52
(14)
: 727
-742
.
DOI: 10.12354/j.issn.1000-8179.2025.20250754